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Tendon healing is fraught with complications such as reruptures and adhesion formation due to the formation of scar tissue at the
injury site as opposed to the regeneration of native tissue. Stem cells are an attractive option in developing cell-based therapies to
improve tendon healing. However, several questions remain to be answered before stem cells can be used clinically. Speciﬁcally, the
typeofstemcell,theamountofcells,andthepropercombinationofgrowthfactorsormechanicalstimulitoinducediﬀerentiation
all remain to be seen. This paper outlines the current literature on the use of stem cells for tendon augmentation.
1.Introduction
Tendons function to transmit force from muscle to bone,
with the ultimate eﬀect of actuating motion. Tendon tissue
has been designed to endure large tensile loads. When
tendons are injured, normal tendon histology is not restored
and, therefore, neither is function. Tendons heal with an
intervening layer of scar tissue. This scar tissue has material
properties that are inferior to native tendon. This makes
surgicalrepairsoftorntendonspronetofailure.Italsomakes
them susceptible to adhesion formation due to excess ﬁbrous
tissue formation. Therapies that can augment regeneration
of normal tendon and limit the amount of scar tissue
that is formed in response to injury may improve clinical
outcomes.
Stem cells have great promise in enhancing the biologic
healingprocesssincetheyprovideaself-renewingpopulation
of pluripotent cells. However, several questions still remain
before stem cells can be used clinically for augmenting
tendonhealing.Speciﬁcally,thetypeofstemcell,theamount
of cells, the combination of growth factors and mechanical
stimuli, and the ideal delivery vehicle all still need to be
determined. The purpose of this paper is to outline the
current research on developing a clinical stem cell therapy
for the augmentation of tendon healing.
2.Typesof StemCells
Stem cells are deﬁned as a population of cells that can self-
renew through symmetrical mitotic division, form daughter
cell lines, and generate a broad range of tissue lineages
through terminal diﬀerentiation [1, 2]. Stem cells can be
derived from a number of sources, and thus diﬀerent stem
cell categories exist. These categories include embryonic,
peri-natal (obtained from the umbilical cord or from amni-
otic tissue), somatic adult, or induced pluripotent stem cells
(iPSCs). While there is some overlap, the most common
categories of adult stem cells are mesenchymal stem cells
(MSCs) and hematopoietic stem cells which are both deﬁned
based upon speciﬁc stem cell surface markers [3]. iPSCs are
not adult stem cells in origin but mature adult cells that are
modiﬁedresultingincellpluripotencyandthecharacteristics
of embryonic cells [4, 5]. This exciting technique holds great
promiseforthefuture,buttherehasbeenverylittleinvestiga-
tionoftheirusefulnessfororthopaedicinterventions.Inview
of ethical concerns and current regulatory issues associated
with embryonic or perinatal stem cells, orthopaedic stem cell
research has predominantly focused upon MSCs.
MSCs (also referred to as mesenchymal stromal cells)
are deﬁned by their ability to self-renew and their multipo-
tentiality [6]. MSCs are deﬁned by three characteristics: (i)
an ability to adhere to plastic, (ii) presentation of stem cell2 Stem Cells International
speciﬁc antigens, and (iii) the potential to form multipotent
mesenchymal cells which can diﬀerentiate into a number
of cell lines interesting to musculoskeletal medicine such as
osteocytes, chondrocytes, and adipocytes [7–9]. No stem-
cell-speciﬁc marker has been isolated to date, although
numerousstem-cell-associatedpositiveandnegativemarkers
have been identiﬁed. Stem cell associated positive markers
include CD 31, 34, 40, 49c, 53, 74, 90, 106, 133, 144, and 163,
as well as cKit and Slams [10–13]. Negative stem cell markers
indicate other cell lineages such as hematopoietic and
endothelial cells and include CD 14, 31, 34, and 45 [14–
17]. Induction of MSCs into speciﬁc cell lineages such as
tenocytes is determined by culturing processes as well as
growth and media conditions (Figure 1).
Bi et al. identiﬁed a tendon progenitor stem cell (TPSC)
populationinbothmiceandhumans[14].Agreaterpropen-
sity of TPSC was identiﬁed in “niches,” or specialized tendon
microenvironments, that contain an array of growth factors
such as biglycan and ﬁbromodulin. TPSC can be diﬀeren-
tiated from tenocytes by the presence of stem cell markers
such as Oct-4, tenomodulin, and SSEA-4 [16]. Multidiﬀer-
entiation potential is maintained within the TPSC popula-
tion as they can diﬀerentiate into tenocytes, chondrocytes,
osteocytes,andadipocytes.ProstaglandinE2 (PGE2),BMP-2,
BMP-12 and -13 TGF-β3, and platelet-rich plasma releasate
are proposed to be important mediators for promoting
stem cell diﬀerentiation into tendon tissue as opposed to
adipocyteandosteocyteformation[15,18].Tendonprogeni-
tor stem cells decrease with age, which may contribute to the
age-related reduction in tendon repair seen in rotator cuﬀ
tears [19]. Increasing the pool of tendon stem may stimulate
increased tendon healing with tendon regeneration rather
than reactive scar formation.
MSCs have been isolated from a number of diﬀerent
tissue sources. The most common sources of MSCs for mus-
culoskeletal applications are bone marrow and adipose tissue
due to their accessibility and the ability to obtain large num-
bers of viable cells [20]. Bone-marrow-derived MSCs have a
greater ability to diﬀerentiate into chondrocytes and osteo-
cytes compared to adipose-derived MSCs [21, 22], although
the latter provides greater ease of access and decreased
donor site morbidity [23]. However, human bone marrow
consists of very low yields of MSCs, accounting for only
0.001–0.01% of total nucleated cells [8]. Less common
sources of MSCs include tendon, muscle, synovium, carti-
lage, skin, peripheral blood, periodontal tissue, hair follicles,
and scalp tissue [18, 24–26] .W h i l eM S C sa r er e l a t i v e l ye a s y
to harvest, there is concern about their ability to eﬃciently
diﬀerentiate into tendon. Research into embryonic, perina-
tal, and iPSCs is fastly emerging, though their usefulness for
tendon augmentation remains to be seen.
3. Untreated Stem Cells
As MSCs possess the potential to diﬀerentiate into tenocytes,
MSC application to torn tendons is proposed to recapitulate
tendon development signals and improve tendon healing
capabilities. MSC-mediated tendon regeneration has been
studied in numerous animal tendon models.
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Figure 1: Pathway of mesenchymal stem cell diﬀerentiation into
tenocytes.
TheadditionofMSCstosemitendinosustendonsinbone
tunnels during anterior cruciate ligament (ACL) reconstruc-
tions promoted improved healing with higher failure loads
and stiﬀness after 8 weeks [27]. Healing occurred through
ﬁbrocartilagenous tissue that resembled the native tendon-
to-bone insertion site rather than the scar tissue typically
seen following injury. Lim et al. also delivered MSCs in a
ﬁbrin glue carrier to tendon grafts in a rabbit ACL recon-
structionmodel[28].At2weeks,largenumbersofimmature
ﬁbrocartilage cells were noted at the tendon enthesis, and,
by 8 weeks, the enthesis resembled a normal ACL insertion
with a mature ﬁbrocartilagenous zone as well as improved
load to failure and stiﬀness properties. In a similar study by
Soon et al., synovium-derived MSCs were added to rabbit
ACL repairs [20]. Compared to the control group without
cells, MCS-coated grafts produced a ﬁbrocartilagenous zone
resembling a normal ACL insertion. While the MSC-treated
group produced signiﬁcantly higher load to failures, it also
had lower stiﬀness and Young’s modulus values suggest-
ing that MSCs mediated a more physiologic regenerative
response.
Awad et al. demonstrated that bone-marrow-derived
stem cells delivered to a patellar tendon wound site resulted
in improved mechanical and some histological properties
[24]. The addition of MSCs resulted in increased maximum
stress, modulus, and strain in addition to improved mature
collagen ﬁbers and cells. However, there was no signiﬁcant
improvement in microstructure compared to the control
group, and ectopic bone formation was also noted.
Another study used a rabbit Achilles model with a 1cm
tendon defect that was augmented with MSCs suspended
in collagen gel that had been contracted onto pretensioned
sutures [29]. MSC treatment resulted in superior load prop-
erties, collagen ﬁber alignment, and cross-sectional area at
up to 12 weeks. Despite the increase in tissue volume,
the regenerated tissue was composed of ﬁbroblast-like cells
rather than tenocytes. A study by Chong et al. reported anStem Cells International 3
early improvement in mechanical and histologic properties
at three, but not six weeks following MSC delivery to a
rabbit Achilles tendon model [25]. Labeled bone-marrow-
derived MSCs were noted to be viable and localized to the
intratendinous region at six weeks, before displaying a more
diﬀuse spread. This suggested that any MSC-mediated accel-
eration in healing occurs during the early phase of healing.
Synovium-derived MSCs have also been shown to accel-
erate early remodelling of Achilles tendons by stimulating
increased collagen ﬁber production at 1 week and ﬁbers
resemblingSharpey’sﬁbersbetweenthetendonandboneat2
weeks [26].
A number of animal studies suggest that simply deliver-
ing stem cells alone not appear to improve tendon healing.
Gulotta et al. showed that the application of bone-marrow-
derived MSCs alone was insuﬃcient to improve rotator cuﬀ
healing in a rat model [30]. The eﬀectiveness of MSCs
may be determined by achieving targeted and sustained
stem cell delivery to the site of tendon defects, as well as
through appropriate modulation of growth factors, cytok-
ines, mechanical environment, and cell concentration.
A few studies have tried to address the eﬀect of diﬀerent
stem cell densities. MSCs were seeded onto collagen matrices
and contracted onto sutures at diﬀerent cells densities of 1,
4, and 8 million cells/mL prior to implantation into rabbit
patellar tendon defects [31]. The repairs with MSC collagen
composites demonstrated signiﬁcantly higher maximum
stresses and moduli, as well as faster healing than repairs
without MSCs. The mechanical improvements did not
correlate with improved histological appearance, although
greater tissue volume was noted. Interestingly, no diﬀerence
was detected between the diﬀerent cell densities, suggesting
that higher MSC concentrations do not necessarily translate
to improved healing. Of concern was the fact that 28% of the
MSC-mediated repairs developed ectopic bone formation
at the repair site. A similar study by Juncosa-Melvin et al.
investigated the eﬀect of seeding diﬀerent MSC densities
onto tissue-engineered constructs to repair patellar defects
in rabbits [32]. No diﬀerences in mechanical properties were
detected between the two cell densities or between patellar
tendon defects treated with or without cells.
Some studies have tried to address whether stem cells
mediate a superior eﬀect on tendon healing compared to
alternative types of diﬀerentiated cells. Hankemeier et al.
used a patellar tendon defect model to compare the eﬀects
of stem cells and human ﬁbroblasts that were both delivered
using a ﬁbrin matrix [33]. Stem cells were found to produce
bettertendonhealingwithasigniﬁcantlyincreasedmeancol-
lagen ﬁbril diameter and area covered by collagen ﬁbrils after
10 but not 20 days, in addition to increased collagen 1 and
3 mRNA expression at 20 days. However, the diﬀerent cell
types did not produce a diﬀerence in mechanical properties,
as measured by ultimate stress.
4. Growth and Differentiation Factors and
Stem Cells
While most animal studies have shown encouraging results
withthesimpleapplicationofuntreatedstemcells,agrowing
consensus exists that optimal therapy will include treatment
of these cells with growth factors. Many studies have demon-
strated that mesenchymal stem cells diﬀerentiate in response
to bone morphogenetic proteins, transforming growth
factors and ﬁbroblast growth factor [34].
Gulotta et al. have studied the eﬀect of various growth or
diﬀerentiation factors and stem cells on tendon healing in a
rat model of rotator cuﬀ repair [35–37]. They did not ﬁnd
any improvement in histologic and biomechanical outcomes
when MSCs were transduced with BMP-13 when compared
to untransduced MSC controls [36]. However, they did ﬁnd
improved healing parameters when MSCs were transduced
with two genes present during tendon development during
embryogenesis, scleraxis [35], and membrane type 1- matrix
metalloproteinase (MT1-MMP) [38]. When MSCs trans-
duced with either scleraxis or MT1-MMP were added to the
healing site, improved histology scores and biomechanical
strength were seen as early as 4 weeks following repair. This
led the authors to conclude that certain growth or diﬀer-
entiation factors will be necessary, in addition to MSCs, in
order to optimize their eﬀectiveness.
In another study, investigating the role of bone morpho-
genetic proteins, Rui et al. modeled calcifying tendinopathy
with an in vitro model that applied uniaxial cyclic loading
to tendon-derived stem cells grown on plates coated with
collagen type I [39]. Increased repetitive tensile loads led
to increased expression of BMP-2 as well as increased cell
alignment along the direction of externally applied tensile
forces. In addition, BMP-2, when added to tendon derived
stem cells, was demonstrated to promote osteogenic diﬀer-
entiation and led to ectopic calciﬁcation.
While growth factor therapy in addition to MSC seems
promising, the question remains as to what factor yields the
best results. The various possible combinations of factors are
daunting, which has led researchers to pursue platelet rich
plasma (PRP) as a way of delivering multiple factors in a
single therapeutic agent. PRP has been shown to inﬂuence
the behavior of stem cells. Using tendon stem cells derived
fromrabbitpatellartendons,ZhangandWangdemonstrated
that increased PRP releasate caused tendon stem cells to
become larger and elongated [18]. PRP releasate increased
tendon stem cell proliferation, induced tendon stem cell dif-
ferentiation into tenocytes, and increased protein expression
and collagen type I and type III production.
5.MechanicalLoadandStemCells
In addition to growth factors, altering the mechanical envi-
ronment is another way to induce stem cell diﬀerentiation
into tenocytes. The mechanical loading of stem cells appears
to guide diﬀerentiation. Sharma and Snedeker combined
mechanical and molecular cues by culturing bone marrow
stromal stem cells on a hydrogel matrix with a gradient of
mechanical compliance as well as gradients of the ligands
ﬁbronectinandcollagentypeI[40].Thesecellsdiﬀerentiated
towards osteogenic precursors on ﬁbronectin and tenogenic
precursors on the collagen substrate. In addition, osteogenic
diﬀerentiation increased on stiﬀer ﬁbronectin substrates and4 Stem Cells International
decreased on collagen substrates. Tenogenic diﬀerentiation
was only observed on collagen substrates within a narrow
range of stiﬀness. Yin et al. further demonstrated that cells
sense matrix topography and that this information eﬀects
gene expression and diﬀerentiation [41]. Human tendon
progenitorcellswereseededonalignedorrandomlyoriented
poly nanoﬁbers. The expression of tendon-speciﬁc genes,
such as integrin alpha 1, alpha 5, and beta 1 subunits and
myosin B was found to be higher in cells growing on aligned
nanoﬁbers than those on randomly oriented nanoﬁbers. In
addition, randomly oriented nanoﬁbers induced osteoge-
nesis, as demonstrated by increased alkaline phosphatase
activity,whilealignedscaﬀoldinghinderedosteogenesis.This
work demonstrates that nanotopography, with an aligned
organization, induces tendon stem cells to form tendon-like
tissue in vivo.
As work progresses on the development of biomimetic
scaﬀolds for tendon tissue, the mechanical loading of tissue
has also been demonstrated to inﬂuence stem cell diﬀeren-
tiation [42]. Zhang and Wang recently demonstrated, in an
in vitro model, how the magnitude of mechanical loading
inﬂuences the route of diﬀerentiation of tendon stem cells
[43].Lowmechanicalstretchingat4%straindirectedtendon
stemcellsintotenocytes,whilestretchingat8%directedstem
cells into adipogenic, chondrogenic, and osteogenic lineages.
ZhangandWangalsoreported,inaliveanimalratstudy,that
treadmillrunningdoubledproliferationratesoftendonstem
cellsin both thepatellaand Achillestendon aswellascellular
production of collagen [44]. In addition, the lab demon-
strated that stem cells isolated from the treadmill group
produced more collagen when cultured with tenocytes than
stemcellsisolatedfromthecagecontrolgroup.Thisindicates
that the proper mechanical loading conditions increase the
proliferation of tendon stem cells as well as cellular pro-
duction of collagen.
While mechanical signals have been shown to aﬀect mes-
enchymal stem cells fate, the characteristics of an eﬀective
loading regimen for tendon-to-bone healing have yet to be
fully determined. Sen et al., using an in vitro model in which
mesenchymal stem cells underwent two twenty-minute
episodes of low intensity vibration or high magnitude strain,
demonstrated that adipogenesis was suppressed and osteo-
genesis was ampliﬁed when there was at least a one-hour
refractory period between bouts [45]. The group further
showed that the eﬀect was enhanced with increasing lengths
of the refractory periods. This work shows that the schedul-
ingofloadingeventsisatleastasimportantasthemagnitude
of the loads.
6.ClinicalApplications ofStemCells
A number of clinical applications for augmenting tissue
healing with stem cells in humans have been reported. MSCs
have been used for human craniofacial tissue regeneration
with varying reports of success [46]. Orthopaedic stem
cell studies in humans have predominantly focused upon
enhancingbonehealing,particularlyinspine,footandankle,
and fracture surgery [47, 48]. Centeno et al. treated 227
patients with autologous MSCs that were cultured and then
injected into peripheral joints (n = 213) or intervertebral
discs (n = 13) [49]. Patients underwent disease surveillance
foranaverageof10.6months,andnomalignanttransforma-
tions were reported. One patient was diagnosed with cancer
which the authors believe was “certainly unrelated” to the
MSC therapy. Seven patients had complications related to
the injection, and 3 possible stem-cell-related complications
were reported. Forty-ﬁve of the patients had serial MRIs
for up to 2 years, and none of the patients showed any
evidence of tumor formation, suggesting that MSC therapy
is a relatively safe and well-tolerated procedure. However,
the few clinical stem cell studies have only reported short-
term outcomes and ideally longer-term followup is required
to determine safety.
Despite the promising MSC-mediated eﬀects on tendon
healing noted in a number of animal studies, there are no
clinical studies examining the eﬃcacy and safety of stem cells
on human tendon repair. However, other cellular therapies
havebeenshowntoclinicallyimprovetendonhealing.Clarke
at al. applied skin-derived tenocyte-like cells to 33 patients
with patellar tendinopathy and compared it to 27 patients
whoweretreatedwithplasma[50].Thegroupreceivingstem
cell treatment noted a signiﬁcant improvement in Victorian
Institute of Sport Assessment (VISA) scores. While both the
cellandplasmagroupsresultedinanimprovementintendon
hypoechogenicity on ultrasound and tear size, only the cell
group showed a signiﬁcant decrease in tendon thickness. A
pilot study of 12 patients with refractory elbow epicondylitis
showedasigniﬁcantimprovementinthepatient-ratedtennis
elbow evaluation scale and ultrasound tendon appearance
[51].
A number of issues regarding the clinical application of
stem cells still need to be addressed. The method of stem
cell aspiration may aﬀect the viability and function of the
cells. Stem cell therapies typically require in vitro culturing
and expansion of cells to obtain suﬃcient numbers of viable
cells prior to reimplantation (Figure 2). This raises a number
of ethical and regulatory concerns. A one-step approach
is increasingly advocated, wherein a suﬃcient number of
stem cells are harvested intraoperatively, concentrated, and
then reimplanted within the same procedure. This technique
is considered an intraoperative procedure using autologous
tissue,andassuchdoesnotrequireFoodandDrugAuthority
(FDA) approval. Hernigou et al. have successfully used this
technique to treat patients with femoral osteonecrosis and
fracture nonunions [52, 53]. A number of commercial bone
marrow aspirate concentration systems are available which
can concentrate cells within an hour.
The source of stem cells may help to determine stem cell
eﬀectiveness. Locally derived stem cells may most likely to
be eﬀective in promoting tendon regeneration, particularly
in view of the importance of tendon “niches” in tenocyte
diﬀerentiation humans [14]. Progenitor cells with osteogenic
potential were aspirated from the proximal humerus of 23
patients during arthroscopic rotator cuﬀ repairs [54]. No
adverse eﬀects of stem cell aspiration were detected on clini-
caloutcomes,althoughtheaspiratedcellswerenotreinjected
into the patients. The authors proposed that the proximalStem Cells International 5
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Figure 2: One potential clinical application of stem cell technology for tendon repair.
h ume rusisane ﬃcientand safesite forharvesting progenitor
cells during rotator cuﬀ repairs. Using a reamer-irrigation-
aspirator (RIA) during reaming of long bones was shown
to permit isolation of MSCs which were comparable to iliac
crest bone-marrow-derived cells in terms of diﬀerentiation
potential and daughter line phenotypes [55]. However, the
RIA produced greater numbers of colony forming units and
total cell numbers compared to collecting cells from the iliac
crest.
Eﬀective translation of promising stem-cell-mediated
tendon healing in animals has not yet been proven in the
clinical setting. A number of concerns exist about MSC use
within humans, such as tumor-like growth of MSCs and
modulation of the immune system. Regardless of the source
of MSCs, there is a risk of diﬀerentiation into undesirable
lineages which could result in ectopic tissue formation and
calcium deposition. Systemic injections of allogeneic MSCs
have been shown to disseminate to a number of organs in
baboons [56]. Some of the potential concerns are associated
with the culturing process of MSCs and include the risk of
genetic alterations, phenotypic drift, as well as transmission
of zoonotic infections from the use of fetal bovine serum
during culturing.
7. Conclusions
Stem cells are an attractive option for the augmentation of
tendon repairs. Embryonic stem cells appear to oﬀer the best
diﬀerentiation potential, but their use is controversial, and
no studies have evaluated their clinical usefulness. Several
s t u d i e sh a v ee v a l u a t e dt h eu s eo fM S C sw i t hs o m es u c c e s s ,
but profound results have been lacking when these cells
are applied untreated. Molecular cues, such as the addition
of BMP’s, MT1-MMP, and scleraxis, and mechanical cues
such as changes in strain and nanotopography, have shown
promising results in their ability to drive MSCs into teno-
cytes diﬀerentiation. Utilizing this knowledge to develop a
clinically useful therapy has yet to be accomplished, but our
understanding of stem cell biology continues to expand with
the hope of one day ﬁnding one.
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